Regorafenib Tablets

Product Details:

Regorafenib, marketed under the brand name Stivarga, is an oral medication used to treat certain types of cancer, including metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. It works by inhibiting multiple protein kinases, which are involved in cancer cell growth and blood vessel formation. 

Key Points about Regorafenib:

Targeted Therapy:

Regorafenib is a targeted therapy, meaning it focuses on specific molecules involved in cancer growth. 

Multi-Kinase Inhibitor:

It inhibits multiple protein kinases, including those involved in angiogenesis (blood vessel formation) and cancer cell signaling. 

Approved Uses:

Metastatic Colorectal Cancer (mCRC): Used after other treatments have failed. 

Gastrointestinal Stromal Tumors (GIST): Used after treatment with imatinib and sunitinib. 

Hepatocellular Carcinoma (HCC): Used after treatment with sorafenib. 

Administration:

It is typically taken orally, with a starting dose of 160 mg daily for the first 21 days of a 28-day cycle. 

Potential Benefits:

Regorafenib can help shrink tumors, slow cancer growth, and potentially extend overall survival. 

Side Effects:

It can cause side effects, including hand-foot syndrome, fatigue, hypertension, and diarrhea. 

Important Considerations:

Clinical Trials:

Regorafenib's effectiveness and safety have been established through clinical trials. 

Individualized Treatment:

Treatment with regorafenib should be tailored to the individual patient, taking into account their specific cancer type, stage, and overall health. 

Monitoring:

Regular monitoring is important to assess the effectiveness of treatment and manage potential side effects.